Analytical Data
-
基因名
CDK6
-
简介
The CDK6ic complex is an important serine/threonine protein kinase that regulates cell cycle progression and differentiation, promoting the G1/S transition by phosphorylating substrates such as pRB/RB1 and NPM1. It interacts with D-type G1 cyclins during interphase to form active pRB/RB1 kinase, which controls cell cycle entry. CDK6 Protein, Human (Sf9, His-Avi) is the recombinant human-derived CDK6, expressed by Sf9 insect cells, with N-His, N-Avi labeled tag. The total length of CDK6 Protein, Human (Sf9, His-Avi) is 326 a.a..
- Application
-
别名
Cyclin-dependent kinase 6; Cell division protein kinase 6; CDKN6; EC:2.7.11.22
-
种属
Human
-
表达系统
Baculovirus
-
标签
N-His;N-Avi
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q00534
-
表达区间
M1-A326
-
蛋白长度
Full Length
-
分子量
41.3 KDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Cyclin-dependent kinase 6 (CDK6) is a critical serine/threonine kinase that plays a vital role in regulating the cell cycle, particularly in transitioning from the G1 phase to the S phase. Its activity is tightly regulated by cyclins and CDK inhibitors, making it an important target for cancer research, especially in tumors with dysregulated cell cycle progression. Overexpression or constant activation of CDK6 has been implicated in various malignancies, including leukemia, breast cancer, and glioblastoma, where it contributes to uncontrolled cellular proliferation. Recent studies have highlighted the potential of CDK6 as a therapeutic target, leading to the development of selective CDK6 inhibitors that can effectively hinder tumor growth while sparing normal cells. The study of recombinant CDK6 proteins provides valuable insights into its structure, function, and interaction with other cellular proteins, facilitating the identification of novel inhibitors and advancing our understanding of CDK6's role in oncogenesis. Through structural biology techniques and biophysical analyses, researchers aim to delineate the molecular mechanisms by which CDK6 contributes to cancer and to explore potential therapeutic strategies aimed at modulating its activity. As our understanding of CDK6 evolves, the development of precise and effective treatment options based on CDK6 modulation holds promise for improving cancer therapeutics and patient outcomes.
